Trial Profile
A phase I/II study of CO 1686 in patients with non-small cell lung cancer and EGFR mutation in Asia
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 30 Mar 2012
Price :
$35
*
At a glance
- Drugs Rociletinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 30 Mar 2012 New trial record